PubMed=16142320; DOI=10.3892/ijo.27.4.1029
Rouslan Kotchetkov, Pablo Hernaiz Driever, Jaroslaw Cinatl, Martin Michaelis, Jana Karaskova, Roman A. Blaheta, Jeremy Andrew Squire, Andreas von Deimling, Jussi Moog, Jindrich Cinatl Jr.;
Increased malignant behavior in neuroblastoma cells with acquired multi-drug resistance does not depend on P-gp expression.
Int. J. Oncol. 27:1029-1037(2005)

PubMed=19147553; DOI=10.1158/0008-5472.CAN-08-1856
Martin Michaelis, Florian Rothweiler, Denise Klassert, Andreas von Deimling, Kristoffer Weber, Boris Fehse, Bernd Kammerer, Hans-Wilhelm Doerr, Jindrich Cinatl Jr.;
Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3.
Cancer Res. 69:416-421(2009)

PubMed=22170099; DOI=10.1038/cddis.2011.129; PMCID=PMC3252738
Martin Michaelis, Florian Rothweiler, Susanne Barth, Jaroslaw Cinatl, Marijke van Rikxoort, Nadine Loschmann, Yvonne Voges, Rainer Breitling, Andreas von Deimling, Franz Rodel, Kristoffer Weber ...Show all 17 authors... , Boris Fehse, Elisabeth Mack, Thorsten Stiewe, Hans-Wilhelm Doerr, Daniel Speidel, Jindrich Cinatl Jr.; Show fewer authors
Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells.
Cell Death Dis. 2:e243.1-e243.8(2011)

PubMed=27517323; DOI=10.18632/oncotarget.11160; PMCID=PMC5295411
Nadine Loschmann, Martin Michaelis, Florian Rothweiler, Yvonne Voges, Barbora Balonova, Barry A. Blight, Jindrich Cinatl Jr.;
ABCB1 as predominant resistance mechanism in cells with acquired SNS-032 resistance.
Oncotarget 7:58051-58064(2016)